| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
P7C3-A20 (P 7C3-A20; P7C3A20) is a P7C3 derivative that acts as a proneurogenic and neuroprotective agent with neuroprotective activity. P7C3-A20 displayed increased activity and an improved toxicity profile compared to P7C3. P7C3-A20 demonstrated greater proneurogenic efficacy than a wide spectrum of currently marketed antidepressant drugs. P7C3-A20 showed neuroprotective properties in rodent models of Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury and age-related cognitive decline.
| ln Vitro |
In PC12 cells, P7C3-A20 (10-100 μM; 8 hours) treatment lessens the cytotoxicity generated by oxygen-reduction enhanced (OGD) [1].
|
|---|---|
| ln Vivo |
In the HI paradigm, P7C3-A20 (5–10 mg/kg; intraperitoneal; daily; 7 days; Sprague-Dawley rats) decreases the number of infarcts, reverses the loss of cells in the retina and hippocampus, and enhances motor function. However, P7C3–A20 cannot stop HI-induced neuronal damage by turning on PI3K/AKT/GSK3β signaling [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: PC12 cells Tested Concentrations: 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, 100 μM Incubation Duration: 8 hrs (hours)) treatment can attenuate OGD-induced PC12 cell sterility[1]. Experimental Results: Mitigated oxygen glucose deprivation (OGD)-induced cytotoxicity in PC12 cells. Apoptosis analysis [1] Cell Types: PC12 Cell Tested Concentrations: 40 μM, 60 μM, 80 μM, 100 μM Incubation Duration: 8 hrs (hours) Experimental Results: Reduce oxygen glucose deprivation (OGD)-induced PC12 cell apoptosis. |
| Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rat (200-250 g) induced hypoxic-ischemic (HI) injury [1]
Doses: 5 mg/kg, 10 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; continued for 7 Day Experimental Results: Reduction in infarct volume; reversal of cell loss in cortex and hippocampus and improvement in motor function without causing neurotoxicity. |
| References |
[1]. Junjie Bai, et al. The Small Molecule P7C3-A20 Exerts Neuroprotective Effects in a Hypoxic-Ischemic Encephalopathy Model via Activation of PI3K/AKT/GSK3β Signaling. Neuroscience. 2020 Jun 3;S0306-4522(20)30353-5.
[2]. Blaya MO et al. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma. 2014 Mar 1;31(5):476-86. [3]. Walker AK et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasinghippocampal neurogenesis. Mol Psychiatry. 2015 Apr;20(4):500-8. |
| Molecular Formula |
C22H19BR2FN2O
|
|---|---|
| Molecular Weight |
506.20546746254
|
| CAS # |
1235481-90-9
|
| Related CAS # |
P7C3;301353-96-8
|
| SMILES |
FC(CNC1=CC(OC)=CC=C1)CN2C3=CC=C(Br)C=C3C4=CC(Br)=CC=C24
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~197.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.85 mg/mL (7.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 38.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9755 mL | 9.8773 mL | 19.7546 mL | |
| 5 mM | 0.3951 mL | 1.9755 mL | 3.9509 mL | |
| 10 mM | 0.1975 mL | 0.9877 mL | 1.9755 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA